6533b827fe1ef96bd128715a

RESEARCH PRODUCT

Salmeterol Xinafoate (SX) loaded into mucoadhesive solid lipid microparticles for COPD treatment

Donatella ValentiMaria Letizia MancaElisabetta PaceMaria FerraroMaria Luisa BondìMark GjomarkajErika AmoreSerena Di VincenzoValeria La ParolaGaetano Giammona

subject

3003AgonistDrugAlginatesCell Survivalmedicine.drug_classmedia_common.quotation_subjectSodium alginate polymerPharmaceutical ScienceChronic obstructive pulmonary disease (COPD)Inflammation02 engineering and technologyPharmacology030226 pharmacology & pharmacyCell LinePulmonary Disease Chronic Obstructive03 medical and health sciences0302 clinical medicinecAMPmedicineHumansAerodynamic diameterAdrenergic beta-2 Receptor AgonistsSalmeterol Xinafoatemedia_commonDrug CarriersCOPDInhalationChemistryTherapeutic effectAdhesiveness021001 nanoscience & nanotechnologymedicine.diseaseLipidsSALMETEROL XINAFOATEBronchodilator Agentsrespiratory tract diseasesSalmeterol Xinafoate (SX)MucusAerodynamic diametermedicine.symptom0210 nano-technology

description

Chronic obstructive pulmonary disease (COPD) is one of the main health problems worldwide. It is characterised by chronic inflammation in the lungs that leads to progressive, chronic, largely irreversible airflow obstruction. The use of long-acting β agonists remain today the frontline treatment for COPD with the aim of minimizing side effects and enhancing therapeutic usefulness. To this purpose, in this paper, mucoadhesive solid lipid microparticles (SLMs) containing a long-acting β-2 agonist, Salmeterol Xinafoate (SX) were prepared, characterised (size, z-potential, aerodynamic diameter, turbidimetric evaluations, drug loading and entrapping efficiency) and tested in a model of bronchial epithelial cells. It was demonstrated that the incorporation of SX into SLMs led to the production of particles suitable for inhalation and more efficient than the free molecule at increasing the cAMP expression in bronchial epithelial cells. In conclusion, the prepared systems, due to their aerodynamic behaviour and mucoadhesive properties, could improve the retention time of SX in the lung epithelium and its therapeutic effect, thus representing a good strategy for the treatment of COPD patients.

yearjournalcountryeditionlanguage
2019-01-01International Journal of Pharmaceutics
https://doi.org/10.1016/j.ijpharm.2019.03.059